Just today, we learned that Verastem, a biotech company that has previously done research in mesothelioma, has now embarked on several new projects.
In the news, announced in a press release, the company lists several projects, including this one:
Clinical Collaboration with Pfizer and Merck KGaA to Evaluate Combination of VS-6063 and Avelumab in Ovarian Cancer –In March 2016, the companies announced their entry into a clinical trial collaboration agreement to evaluate the investigational combination of Verastem’s focal adhesion kinase (FAK) inhibitor VS-6063 and Pfizer/Merck KGaA’s anti-PD-L1 immunotherapy avelumab. Verastem has previously reported initial signs of clinical activity in patients with ovarian cancer when VS-6063 is used in combination with paclitaxel. Under the terms of the agreement, the parties will conduct a planned Phase 1/1b clinical trial evaluating escalating doses of the combination of VS-6063 and avelumab as a potential treatment option for patients with advanced ovarian cancer.
“We are very excited to learn about these new ventures, and Verastem’s further investment into cancer research,” said the executive director of the Meso Foundation, Mary Hesdorffer, APRN. “We wish them the best as they continue to advance this important science.”